Literature DB >> 12806431

Role of fractalkine in leukocyte adhesion and migration and in vascular injury.

H Umehara1, T Imai.   

Abstract

Leukocyte adhesion and trafficking at the endothelium requires both cellular adhesion molecules and chemotactic factors. Fractalkine, a recently identified chemokine, has a unique architecture, a Cys-X-X-X-Cys chemokine domain presented on top of an extended mucin-like stalk as a part of transmembrane protein, and is expressed in a membrane-bound form on tumor necrosis factor-alpha and interleukin-1-activated endothelial cells. Fractalkine receptor CX3CR1 is expressed on natural killer (NK) cells, monocytes and some portions of CD8(+) T cells. Interactions between fractalkine and CX3CR1 can mediate not only chemotaxis but also cell adhesion in the absence of substrates for other adhesion molecules. Furthermore, fractalkine activates NK cells, resulting in enhanced cytolysis of fractalkine expressing endothelial cells. Since endothelial cells are primary targets of immunologic attack, fractalkine seems to be involved in pathogenesis of vascular injury. (c) 2001 Prous Science. All rights reserved.

Entities:  

Year:  2001        PMID: 12806431     DOI: 10.1358/dnp.2001.14.8.858415

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  10 in total

1.  Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells.

Authors:  Cynthia A Bolovan-Fritts; Rodney N Trout; Stephen A Spector
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage.

Authors:  Cynthia A Bolovan-Fritts; Rodney N Trout; Stephen A Spector
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

Review 3.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 4.  The blood-brain barrier, chemokines and multiple sclerosis.

Authors:  David W Holman; Robyn S Klein; Richard M Ransohoff
Journal:  Biochim Biophys Acta       Date:  2010-08-06

5.  Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction.

Authors:  Cynthia A Bolovan-Fritts; Stephen A Spector
Journal:  Blood       Date:  2007-09-25       Impact factor: 22.113

6.  NF-kappaB activity in endothelial cells is modulated by cell substratum interactions and influences chemokine-mediated adhesion of natural killer cells.

Authors:  Shmuel Hess; Heiko Methe; Jong-Oh Kim; Elazer R Edelman
Journal:  Cell Transplant       Date:  2009       Impact factor: 4.064

7.  Low shear stress upregulates the expression of fractalkine through the activation of mitogen-activated protein kinases in endothelial cells.

Authors:  Amanguli Ruze; Yiwei Zhao; Hui Li; Xiayimaidan Gulireba; Jing Li; Dongyu Lei; Hongyan Dai; Jiang Wu; Xin Zhao; Yongmei Nie
Journal:  Blood Coagul Fibrinolysis       Date:  2018-06       Impact factor: 1.276

8.  Role of Fractalkine-CX3CR1 Axis in Acute Rejection of Mouse Heart Allografts Subjected to Ischemia Reperfusion Injury.

Authors:  Taichi Kanzawa; Daisuke Tokita; Kan Saiga; Takafumi Yamakawa; Hidetoshi Ishigooka; Hironori Fukuda; Haruki Katsumata; Satoshi Miyairi; Rumi Ishii; Toshihito Hirai; Toshio Imai; Masayoshi Okumi; Kazunari Tanabe
Journal:  Transpl Int       Date:  2022-02-01       Impact factor: 3.782

9.  CX3CR1 receptor polymorphisms, Th1 cell recruitment, and acute myocardial infarction outcome: looking for a link.

Authors:  S Pucci; P Mazzarelli; M J Zonetti; T Fisco; E Bonanno; L G Spagnoli; A Mauriello
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

10.  Microvesicles derived from human Wharton's Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1.

Authors:  Xiangyu Zou; Guangyuan Zhang; Zhongliang Cheng; Deming Yin; Tao Du; Guanqun Ju; Shuai Miao; Guohua Liu; Mujun Lu; Yingjian Zhu
Journal:  Stem Cell Res Ther       Date:  2014-03-19       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.